Solu-Medrol lyophilizate d / pr.r-ra for v / ven. and v / mouse. enter 500 mg vials + solution 7.8 ml 1 pc. (Methylprednisolone)

Latin name

Solu-Medrol

Release form

Lyophilisate for preparation for injection for injection

Packaging

In a pack of 1 bottle complete with solvent.

Pharmacological action of

Solu-Medrol - the drug is an injectable form of methylirednisolone, a synthetic glucocorticosteroid (GCS), for intramuscular (intramuscular) and intravenous (iv) administration.

corticosteroids penetrate cell membranes and form complexes with specific cytoplasmic receptors. Then these complexes penetrate the cell nucleus, bind to DNA (chromatin) and stimulate the transcription of mRNA and the subsequent synthesis of various enzymes, which explains the effect of corticosteroids during systemic use.

corticosteroids not only have a significant effect on the inflammatory process and the immune response, but also affect carbohydrate, protein and fat metabolism. In addition, they affect the cardiovascular system, skeletal muscles and the central nervous system.

Most indications for the use of corticosteroids are due to their anti-inflammatory, immunosuppressive and anti-allergic properties. Thanks to these properties, the following therapeutic effects are achieved:

decrease in the number of immunoactive cells near the site of inflammation

decrease in vasodilation

stabilization of lysosomal membranes

inhibition of phagocytosis

decrease in the production of prostaglandins and related compounds.

Methylprednisolone has a strong anti-inflammatory effect, and its activity exceeds that of irednisolone, and the ability to cause water and sodium ion retention is reduced compared to prednisolone.

Metabolism and the anti-inflammatory mechanism of methylprednisolone sodium succinate are similar to those for methylprednisolone. With parenteral administration of equivalent amounts, the biological activity of both compounds is the same.

With the on / in the ratio of the activities of methylprednisolone sodium succinate and hydrocortisone sodium succinate, calculated to reduce the number of eosinophils, is at least 4: 1. This correlates well with the data on the relative activity of methylprednisolone and hydrocortisone when administered orally.

A dose of 4 mg methylprednisolone has the same glucocorticosteroid (anti-inflammatory) effect as 20 mg hydrocortisone. Methylprednisolone has only negligible mineralocorticosteroid activity (200 mg of methylprednisolone is equivalent to 1 mg of deoxycorticosterone).

corticosteroids have lipolytic activity, mainly extending to the fatty tissue of the limbs. In addition, corticosteroids exhibit a lipogenic effect, which most affects the area of ​​the food cell, neck and head. All this leads to the redistribution of the fat depot in the patient's body.

corticosteroids have a catabolic effect on proteins. The released amino acids are converted during gluconeogenesis in the liver to glucose and glycogen.

The consumption of glucose in peripheral tissues is reduced, which can lead to hyperglycemia and glucosuria, especially in patients at risk of developing diabetes. The maximum pharmacological activity of corticosteroids is not manifested at the peak concentration in the blood plasma, but after it, therefore, the action of corticosteroids is due primarily to their effect on the activity of enzymes.

Pharmacokinetics

With any method of introducing methylprednisolone sodium, succinate is significantly and rapidly hydrolyzed by cholinesterase to form the active form - free methylprednisolone. After iv infusion of 30 mg / kg for 20 minutes, or 1 g within 30-60 minutes, after about 15 minutes, a peak in plasma methylprednisolone concentration is reached (about 20 μg / ml).

After about 25 minutes after the iv bolus of 40 mg methylprednisolone, a peak in plasma concentration of 42-47 μg / 100 ml is reached. With a / m administration of 40 mg after 120 minutes, the level of methylprednisolone in the blood plasma is reached, equal to 34 μg / 100 ml. With the / m introduction, a lower peak value is achieved than with the / in the introduction.

The average maximum plasma concentration (Cmax) is reached 1 hour after the intramuscular injection of 40 mg of methylprednisolone sodium succinate and is 454 ng / ml. After 12 hours, the concentration of methylprednisolone in blood plasma decreases to 31.9 ng / ml, and after 18 hours, methylprednisolone is not detected in the blood.

Comparison of the areas under the concentration-time curve indicates the same effectiveness with iv and iv administration of equivalent doses of methylprednisolone sodium succinate.

After i / m administration, the drug is present in blood plasma for a longer period than after i / v administration if an equivalent amount of methylprednisolone is administered. Taking into account the mechanism of action of methylprednisolone, we can assume that these differences have minimal clinical significance.

The clinical effect is usually observed 4-6 hours after administration. In the treatment of bronchial asthma, the first positive results are detected after 1-2 hours. The half-life (T1 / 2) of methylprednisolone sodium succinate from blood plasma is 2.3-4 hours and probably does not depend on the route of administration. The distribution volume is approximately 1, 4 ml / kg and a total clearance of 5-6 ml / min / kg.

Methylprednisolone - GCS with an intermediate duration of action. Its T | d from the human body is 12-36 hours. Due to intracellular activity, a pronounced difference is revealed between T | d of methylprednisolone from blood plasma and T q from the body as a whole.

The pharmacotherapeutic effect persists even when the drug is no longer detected in the blood. The duration of the anti-inflammatory activity of methylprednisolone is approximately equal to the duration of suppression of the hypothalamic-pituitary-adrenal (GGN) system.

The association of methylprednisolone with plasma proteins (albumin and a corticosteroid-binding globulin) is approximately 40-90%.

Metabolism of methylprednisolone is carried out in the liver, mainly using the isoenzyme CYP3A4, and this process is qualitatively similar to the metabolism of cortisol. The main metabolites are 20β-hydroxymethylprednisolone and 20β-hydroxy-6β-methylprednisone.

Metabolites are excreted mainly through the kidneys, both in an unbound form and in the form of glucuronides and sulfates, which are formed mainly in the liver and partially in the kidneys. After iv administration of 14C-labeled methylprednisolone, 75% of the total radioactivity is excreted through the kidneys for 96 hours, 9% is excreted through the intestines for 5 days, and 20% is found in bile.

Methylprednisolone is actively distributed in body tissues, passes through the blood-brain barrier, and is excreted in breast milk.

Methylprednisolone is a substrate of the CYP3A4 isoenzyme. The CYP3A4 isoenzyme is the main isoenzyme in the most common subfamily of CYP isoenzymes in the adult liver.

This isoenzyme catalyzes beta-hydroxylation of steroids - the main stage of the first phase of the metabolism of both endogenous and synthetic corticosteroids. Many other compounds are also substrates of the CYP3A4 isoenzyme, some of them (as well as other drugs) affect the metabolism of methylprednisolone by inducing or inhibiting the CYP3A4 isoenzyme.

Like many other substrates of the CYP3A4 isoenzyme, methylprednisolone can also be a substrate of ATP-linked transport proteins of P-glycoprotein, affecting tissue distribution and interaction with other drugs.

In case of impaired renal function, dose adjustment is not required. Methylprednisolone is excreted during hemodialysis.

Indications

Endocrine diseases

primary and secondary adrenal insufficiency (if necessary in combination with mineralocorticosteroids, especially in pediatric practice)

acute adrenal insufficiency (it may be necessary to add mineralocorticosteroids)

shock resulting from adrenal insufficiency, or shock, if symptomatic therapy is ineffective when adrenal insufficiency is possible (if a mineralocorticosteroid period is not recommended before) in case of severe trauma or serious illness, in patients with an established or suspected adrenal insufficiency

awn Congenital adrenal hyperplasia

subacute thyroiditis

hypercalcemia on the background of cancer.

Rheumatic diseases (as an additional treatment for short-term relief from an acute condition or during an exacerbation)

post-traumatic osteoarthritis

synovitis with osteoarthritis

rheumatoid arthritis, including juvenile rheumatoid arthritis (in some cases it may be necessary to maintain acute short-term acute epicondylitis.

acute nonspecific tendosynovitis

acute gouty arthritis

psoriatic arthritis

ankylosing spondylitis.

Systemic diseases of the connective tissue (during an exacerbation or in some cases as maintenance therapy)

systemic lupus erythematosus (and lupus nephritis)

acute rheumatic carditis

systemic dermatomyositis (polymyositis)

nodular periarteritis

syndrome Good.

Skin diseases

pemphigus

severe erythema multiforme (Stevens-Johnson syndrome)

exfoliative dermatitis

severe psoriasis

herpetiform bullous dermatitis

severe seborrheic dermatitis

fungal mycosis.

Allergic conditions (in case of severe or disabling conditions, in which conventional therapy is ineffective)

bronchial asthma

contact dermatitis

atopic dermatitis

serum disease

seasonal or perennial allergic rhinitis

drug hypersensitivity reactions

post-transfusion urticaria

Eye diseases (severe acute and chronic allergic and inflammatory processes with eye damage)

ophthalmic form Herpes zoster

iritis and iridocyclitis

chorioretinitis

diffuse posterior uveitis and choroiditis

neuritis sverdkrrdlrd srdlkrdrdrd corneal ulcers

keratitis.

Diseases of the gastrointestinal tract (for removing a patient from a critical condition)

ulcerative colitis

regional enteritis.

Respiratory tract disease

symptomatic sarcoidosis

berylliosis

fulminant and disseminated pulmonary tuberculosis in combination with appropriate anti-tuberculosis chemotherapy

Leffler's syndrome, not amenable to therapy with other means of

aspiration pneumonitis.

Hematologic diseases

acquired (autoimmune) hemolytic anemia

idiopathic thrombocytopenic purpura in adults (only intravenous i / m administration is contraindicated)

secondary thrombocytopenia in adults

erythroblastopenemia erythroblastopenemia erythroblastopenemia (erythroblastopenemia (erythroblastopenemia) erythroblastopenemia (erythroblastopenemia

Oncological diseases (as palliative therapy)

leukemia and lymphoma in adults

acute leukemia in children

to improve the quality of life of patients with cancer in the terminal stage.

Edematous

syndrome to stimulate diuresis and achieve remission of proteinuria in patients with nephrotic syndrome without uremia.

Nervous system

brain edema caused by a tumor - primary or metastatic, and / or associated with surgical or radiation therapy

exacerbation of multiple sclerosis

acute traumatic injuries of the spinal cord. Treatment should begin in the first 8 hours after the injury.

Other indications for use

tuberculous meningitis with subarachnoid block or block threat (in combination with appropriate anti-tuberculosis chemotherapy)

trichinosis with damage to the nervous system or myocardium

organ transplantation

prevention of nausea and vomiting related diseases.

Use in children

The use of the drug in children during the growth period is possible only according to absolute indications and with especially careful monitoring by the attending physician.

Contraindications

Systemic fungal infections.

Hypersensitivity to any component of the drug in history.

It is not recommended to use the drug in patients with acute and subacute myocardial infarction, since the use of glucocorticosteroids in them can lead to the spread of the focus of necrosis, slow the formation of scar tissue and, as a result, to rupture of the heart muscle.

Caution:

In patients with herpes simplex virus eye damage, as this may result in corneal perforation.

With ulcerative colitis, if there is a threat of perforation, abscess or other purulent infection.

For diverticulitis.

In the presence of fresh intestinal anastomoses.

With active or latent peptic ulcer.

Renal failure.

Arterial Hypertension.

Osteoporosis.

myasthenia gravis.

This medication contains gasoline alcohol. It has been established that gasoline alcohol can cause lethal suffocation syndrome in premature infants. The drug is not recommended for use in newborns.

Use in pregnancy and lactation

A number of animal studies have shown that administration of high doses of GCS to females can lead to malformations in the fetus. However, a number of clinical studies have shown that the use of corticosteroids during pregnancy, apparently, does not cause congenital anomalies.

In one retrospective study, there was an increase in the incidence of low birth weight infants in mothers who received corticosteroids. Since studies on pregnant women do not exclude the possible harm of GCS, the use of these drugs during pregnancy, in nursing mothers or women of childbearing age, requires an assessment of the likely positive effect of the drug in comparison with the potential risk to the mother, embryo or fetus.

GCS should be prescribed during pregnancy only by absolute indications.

corticosteroids easily cross the placenta. Although in infants born to mothers who received significant doses of GCS during pregnancy, adrenal insufficiency is rare, such children should be carefully examined to identify possible symptoms of adrenal hypofunction. The effect of GCS on the course and outcome of labor is unknown.

GCS is excreted in breast milk, therefore, if it is necessary to prescribe the drug SOLU-MEDROL during breastfeeding, breast-feeding should be discontinued.

Composition

1 vial contains:

Active ingredient:

methylprednisolone (as sodium succinate) 500 mg

Excipients:

monobasic sodium phosphate

monohydric sodium phosphate.

Dosing and Administration

Solu-medrol can be given as an intravenous or intramuscular injection or as an intravenous infusion, but in case of emergency, treatment should preferably be started with an intravenous injection. Children should be given lower doses (but not less than 0.5 mg / kg / day), however, when choosing a dose, the severity of the condition and the patient's response to therapy are taken into account first, and not age and body weight.

As an adjunctive therapy for life-threatening conditions,

30 mg / kg iv body weight for at least 30 minutes. The introduction of this dose can be repeated every 4-6 hours for a maximum of 48 hours.

Pulse therapy in the treatment of diseases in which corticosteroid therapy is effective, with exacerbations of the disease and / or with the failure of standard therapy.

Recommended treatment regimens:

Rheumatic diseases: 1 g / day iv for 1 to 4 days or 1 g / month iv for 6 months.

Systemic lupus erythematosus: 1 g / day iv for 3 days.

Multiple sclerosis: 1 g / day iv for 3 or 5 days.

Edematous conditions, for example, glomerulonephritis, lupus nephritis: 30 mg / kg every other day for 4 days or 1 g / day iv for 3, 5 or 7 days

The above doses should be administered for at least 30 minutes, and the introduction can be repeated if no improvement has been achieved within a week after the treatment, or if the condition of the patient requires it.

Oncological diseases in the terminal stage - to improve the quality of life

125 mg / day iv daily for up to 8 weeks.

Prevention of nausea and vomiting associated with chemotherapy for cancer

With chemotherapy drugs, with a slight or moderate vomiting effect, 250 mg iv are administered for at least 5 minutes one hour before the administration of a chemotherapeutic drug, at the beginning of chemotherapy, and also after its completion. To enhance the effect with the first dose of the drug Solu-medrol, chlorphenothiazine preparations can be administered.

During chemotherapy with drugs that have a pronounced emetic effect, 250 mg iv are administered for at least 5 minutes in combination with appropriate doses of metoclopramide or butyrophenone one hour before the chemotherapeutic drug is administered, then 250 mg iv at the beginning of chemotherapy and after her graduation.

Acute traumatic injury to the spinal cord

Treatment should be started in the first 8 hours after the injury. Intravenous bolus is recommended for 15 minutes 30 mg / kg body weight, then take a break for 45 minutes, and then carry out continuous infusion at a dose of 5.4 mg / kg / h for 23 hours (if treatment is started in the first 3 hours after injury) or 47 hours (if treatment is started in the first 3-8 hours after injury). The drug should be administered using an infusion pump into an isolated vein.

For other indications, the initial dose is 10-500 mg iv depending on the nature of the disease. For a short course in severe acute conditions, higher doses may be required. An initial dose not exceeding 250 mg should be administered iv for at least 5 minutes, doses over 250 mg should be administered for at least 30 minutes. Subsequent doses are administered intravenously or intramuscularly, and the duration of the intervals between administrations depends on the patient's response to therapy and on his clinical condition.

Preparation of

solutions Preparations for parenteral administration should, if possible, be visually checked for discoloration or particle formation.

a) Act-0-Vial

two-bottle vial Press on the plastic activator so that the solvent overflows into the lower container.

Gently shake the vial until the lyophilisate dissolves.

Remove the plastic disc covering the center of the plug.

Treat the cork surface with an appropriate antiseptic.

Pierce the center of the plug with the needle so that the tip of the needle is visible. Turn the bottle over and take the required amount of solution with a syringe.

b) Bottle

Aseptically, introduce the solvent into the bottle with lyophilisate. Use only special solvent.

c) Preparation of solutions for intravenous infusion

Prepare the solution as described above. The drug can also be introduced in the form of diluted solutions obtained by mixing the initial solution of the drug with 5% aqueous dextrose solution, with physiological saline, with 5% dextrose solution in 0.45% or 0.9% sodium chloride solution. The prepared solutions are physically and chemically stable for 48 hours.

Side effects of

On the part of water-electrolyte metabolism: sodium retention, chronic heart failure in patients with an appropriate predisposition, fluid and salt retention in the body, increased excretion of potassium, hypokalemic alkalosis.

From the cardiovascular system: increase or decrease in blood pressure, cardiac arrhythmias (arrhythmias, bradycardia, tachycardia) chronic heart failure (in patients with predisposition) in patients with acute and subacute myocardial infarction - the spread of the focus of necrosis, slowing the formation of scar tissue, which can lead to rupture of the heart muscle.

There are reports of cardiac arrhythmias and / or the development of circulatory collapse and / or cardiac arrest after rapid iv administration of high doses of methylprednisolone (more than 0.5 g administered for less than 10 minutes). During and after iv administration of high doses of methylprednisolone, cases of bradycardia were also noted, but they did not necessarily depend on the speed or duration of the infusion.

From the musculoskeletal system: osteonecrosis, myopathy, muscle weakness, osteoporosis, pathological fractures, muscle atrophy, neuropathic atrophy, arthralgia, myalgia, compression fractures of the vertebrae, aseptic necrosis of the epiphyses of the tubular bones, tendon ruptures, especially

Acute myopathy most often develops when high doses of methylprednisolone are used in patients with impaired neuromuscular transmission (e.g., with gravis myasthenia gravis), or in patients simultaneously receiving treatment with anticholinergics, such as peripheral muscle relaxants (e.g., pancuronium bromide).

Such acute myopathy is generalized in nature, can affect the muscles of the eye and respiratory system, leading to the development of tetraparesis. Possible increase in creatine kinase levels. In this case, improvement or recovery after the cancellation of methylprednisolone can occur only after many weeks or even after several years.

From the digestive system: peptic ulcer with possible perforation and bleeding, gastric bleeding, pancreatitis, peritonitis, esophagitis (including), perforation of the intestinal wall, abdominal pain, tension of the abdominal wall, diarrhea, dyspepsia, flatulence, nausea, vomiting, stubborn hiccups.

After treatment with methylprednisolone, an increase in the activity of plasma alanine aminotransferase (ALT), aspartate aminotransferase (ACT), and alkaline phosphatase was observed. Typically, these changes are insignificant, not associated with any clinical syndromes, and are reversible after discontinuation of treatment.

From the skin: angioedema, peripheral edema, skin asrophy, skin stretch marks, petechiae and ecchymosis, decreased skin pigmentation, hirsutism, rash, erythema, skin itching, urticaria, acne, slow healing of wounds, reactions at the injection site.

From the side of metabolism: negative nitrogen balance (increased protein breakdown) due to protein catabolism, slowdown of growth and the process of ossification in children (premature closure of the pineal gland growth zones), increased appetite (can lead to increased body weight), increased sweating.

From the nervous system: increased intracranial pressure with swelling of the optic nerve (benign intracranial hypertension), convulsions, amnesia, thinking disorders, dizziness, headache, affective disorders (including lability of mood, depressed mood, euphoria, psychological dependence, thinking), psychotic disorders (including mania, dyslusions, hallucinations, schizophrenia or its aggravation), confusion, mental disturbance, anxiety, personality change , Rapid mood changes, unusual behavior, insomnia, irritability.

From the endocrine system: menstrual irregularities, Itsenko-Cushing's syndrome, hypopituitarism, the development of the “withdrawal” syndrome of steroid drugs, a decrease in glucose tolerance, an increase in the need for insulin or gioglyxmic drugs for oral administration in patients with diabetes mellitus, growth retardation in children, lipomatosis, latent diabetes mellitus.

Laboratory indicators: increased plasma urea concentration, dyslipidemia, increased urinary calcium concentration, hypocalcemia.

From the sensory organs: posterior subcapsular cataract, increased intraocular pressure, glaucoma, exophthalmos, vertigo, secondary fungal or viral ocular infection, perforation of the cornea (with ocular manifestations of herpes simplex).

From the side of the immune system: infectious diseases, the occurrence of infections caused by opportunistic pathogens, hypersensitivity reactions, including anaphylaxis with or without circulatory collapse, cardiac arrest, bronchoslasma, suppression of reactions during skin tests.

Other: fatigue, weakness.

Drug Interaction

Compatibility and stability of solutions of sodium succinate methylprednisolone sodium when administered with / in other medicines included in mixtures for intravenous administration, depend on p H, concentration, time, temperature, and the solubility of methylprednisolone itself.

SALT-MEDROL is recommended to be administered separately from other medicines, if possible, in the form of bolus injections, in / in a drip infusion, or through an additional dropper as a second solution.

The following drug interaction examples may have important clinical implications.

The combined use of methylprednisolone and cyclosporine causes mutual inhibition of metabolism, so it is likely that the side effects associated with the use of each of these drugs as monotherapy, when co-administered, may occur more frequently.

Cases of cramps have been reported with the combined use of these drugs. Drugs that activate liver enzymes, such as phenobarbital, phenytoin and rifampicin, may increase the clearance of methylprednisolone, which may require increasing the dose of the drug to obtain the desired effect.

CYP3A4 inhibitors (such as macrolide antibiotics, azole antifungals, some calcium channel blockers) can suppress methylprednisolone metabolism and reduce its clearance. In this case, to avoid the effects of overdose, you should reduce the dose of methylprednisolone.

Methylprednisolone can increase the clearance of acetylsalicylic acid, taken in high doses over a long period, which may reduce serum salicylates or increase the risk of salicylate toxicity with methylprednisolone withdrawal. In patients with hypoprotrombinemia, acetylsalicylic acid in combination with ACS should be administered with caution.

Methylprednisolone has a variety of effects on the action of oral anticoagulants. Both enhancement and reduction of the effect of anticoagulants taken with methylprednisolone have been reported. In order to maintain the desired anti-coagulant effect, a constant determination of coagulation indices is required.

Overdose

The clinical syndrome of acute drug overdose has not been described. Acute toxicity reports of ACS overdose are extremely rare. There is no specific antidote. Treatment is symptomatic. Methylprednisolone is excreted in dialysis.

Storage conditions

In a dry, dark place, at a temperature not exceeding 20 ° C.

Expiration

5 years.

Deystvuyuschee substances

methylprednisolone



pharmacy leave with

dosage form

dosage form and

injection and infusion



Solu-Medrol lyophilizate d / pr.r-ra for v / ven. and v / mouse. enter 500 mg vials + solution 7.8 ml 1 pc. (Methylprednisolone) florida in pharmacy online. Cheap price, instruction, side effects, dosage. Solu-Medrol lyophilizate d / pr.r-ra for v / ven. and v / mouse. enter 500 mg vials + solution 7.8 ml 1 pc. - Sale. PayPal accept. Free shipping florida. Fast international shipping.